Harada M - Search Results

1

Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma.

Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, Yoshimura K, Harashima N, Harada M, Uemura H. Minami T, et al. Among authors: harada m. Int Immunopharmacol. 2014 May;20(1):59-65. doi: 10.1016/j.intimp.2014.02.018. Epub 2014 Feb 26. Int Immunopharmacol. 2014. PMID: 24583149

2

Serine proteinase inhibitor 9 can be recognized by cytotoxic T lymphocytes of epithelial cancer patients.

Tanaka K, Harashima N, Niiya F, Miyagi Y, Hida N, Ochi M, Imai N, Harada M, Itoh K, Shichijo S. Tanaka K, et al. Among authors: harada m. Jpn J Cancer Res. 2002 Feb;93(2):198-208. doi: 10.1111/j.1349-7006.2002.tb01259.x. Jpn J Cancer Res. 2002. PMID: 11856484 Free PMC article.

3

Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients.

Kobayashi K, Noguchi M, Itoh K, Harada M. Kobayashi K, et al. Among authors: harada m. Cancer Sci. 2003 Jul;94(7):622-7. doi: 10.1111/j.1349-7006.2003.tb01493.x. Cancer Sci. 2003. PMID: 12841872 Free PMC article.

4

Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.

Harada M, Kobayashi K, Matsueda S, Nakagawa M, Noguchi M, Itoh K. Harada M, et al. Prostate. 2003 Oct 1;57(2):152-9. doi: 10.1002/pros.10280. Prostate. 2003. PMID: 12949939

5

HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.

Ishihara Y, Harada M, Azuma K, Tamura M, Shomura H, Fujii T, Itoh K, Shichijo S. Ishihara Y, et al. Among authors: harada m. Int J Oncol. 2004 Apr;24(4):967-75. Int J Oncol. 2004. PMID: 15010837

6

A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.

Matsueda S, Yao A, Ishihara Y, Ogata R, Noguchi M, Itoh K, Harada M. Matsueda S, et al. Among authors: harada m. Prostate. 2004 Aug 1;60(3):205-13. doi: 10.1002/pros.20038. Prostate. 2004. PMID: 15176050

7

Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients.

Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Ogata R, et al. Among authors: harada m. Prostate. 2004 Sep 1;60(4):273-81. doi: 10.1002/pros.20078. Prostate. 2004. PMID: 15264237

8

Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Harada M, et al. Oncol Rep. 2004 Sep;12(3):601-7. Oncol Rep. 2004. PMID: 15289844

9

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients.

Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K. Noguchi M, et al. Among authors: harada m. Prostate. 2005 Apr 1;63(1):1-12. doi: 10.1002/pros.20157. Prostate. 2005. PMID: 15378520 Clinical Trial.

10

New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.

Yao A, Harada M, Matsueda S, Ishihara Y, Shomura H, Takao Y, Noguchi M, Matsuoka K, Hara I, Kamidono S, Itoh K. Yao A, et al. Among authors: harada m. Prostate. 2005 Feb 15;62(3):233-42. doi: 10.1002/pros.20133. Prostate. 2005. PMID: 15389794

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,935 results

Search Page

Filters